Lakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024. In the quarter to June 2026, revenue fell 95.4%, EPS grew 198.9% and free cash flow grew 18.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow LKFT
Lakefront Biotherapeutics - Sponsored ADR (LKFT) EV/Sales
As of 16 October 2026, Lakefront Biotherapeutics - Sponsored ADR (LKFT) trades at a EV/Sales of −2.2×. Over the past ten years it has ranged from −6.1× (May 2026) to 47.6× (January 2018); the current reading is higher than 42% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −3.2× | — |
| FY2024 | −3.4× | — |
| FY2023 | −2.4× | — |
| FY2022 | −2.6× | — |
| FY2021 | −3.4× | — |
| FY2020 | 0.9× | (82.61%) |
| FY2019 | 5.4× | (37.23%) |
| FY2018 | 8.7× | (74.40%) |
| FY2017 | 33.9× | 15.42% |
| FY2016 | 29.4× | 7.33% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | −5.3× | — |
| Mar 2025 | −4.2× | — |
| Mar 2024 | −3.2× | — |
| Sep 2023 | −3.2× | — |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LKFT Lakefront Biotherapeutics - Sponsored ADR | −2.2× |
| PHVS Pharvaris N.V. compare | n/m |
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| VERA Vera Therapeutics, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | 1.0× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 5.3× |
| VCEL Vericel Corporation compare | 6.2× |
| AGIO Agios Pharmaceuticals, Inc. compare | 12.7× |
| IMNM Immunome, Inc. compare | 107× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)